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Epidemiological studies demonstrate an increased risk of colorectal cancer in patients with
inflammatory bowel disease (IBD). A detailed literature review was conducted on epidemiology,
risk factors, pathophysiology, chemoprevention and outcomes of colorectal cancer (CRC) in IBD
as part of the 3rd ECCO scientific pathogenesis workshop.
Crown Copyright © 2013 Published by Elsevier B.V. on behalf of European Crohn's and Colitis
Organisation. All rights reserved.Contents
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We conducted a detailed literature review on epidemiology,
risk factors, pathophysiology, chemoprevention and outcomes
of colorectal cancer (CRC) in inflammatory bowel disease (IBD)
as part of the 3rd ECCO scientific pathogenesis workshop. The
results of a literature search are presented here.
2. Epidemiology of colorectal cancer in IBD
2.1. Methodological considerations
IBD is associated with an increased risk of CRC, which is
thought to be primarily related to long-standing chronicinflammation.1 However, the magnitude of the risk has been
difficult to estimate, as many factors may bias study results2
including patient selection, number of patients, completeness
of case recruitment and ascertainment and duration of
follow-up.2,3
Early studies from tertiary referral centres reported a high
risk of CRC, but as more severe cases were included, they
tended to overestimate the risk. In contrast, population-based
studies covering defined geographical areas report a more
conservative risk. However, these studies probably included
patients with limited and less severe disease, and may have
underestimated the risk. In addition, geographical differences
have been described, with an increased incidence of IBD-
related CRC reported in the USA and in the UK compared with
Scandinavia.4 Similarly, the 10-year follow-up of the European
7Colorectal cancer in inflammatory bowel diseaseCollaborative IBD inception cohort showed that Northern
European centres had higher rates of IBD-related CRC than
Southern centres (prevalence 0.9% vs. 0.25%, respectively; p =
0.17),5 although this North-South gradient was not apparent at
15 year follow-up.6 Similarly, studies from Asian countries
have shown important differences between countries.7–102.2. Epidemiology of colorectal cancer in
ulcerative colitis
In 2001, ameta-analysis of cohort and case-controlled studies4
on the risk of CRC in UC estimated an incidence rate of 3/1000
person years disease duration (PYD), an annual risk of 0.3%
and a cumulative risk of 18.4% after 30 years of disease. The
incidence rate progressively increased each decade from
2/1000 PYD to 7/1000 for the second and 12/1000 for the third
decade.
More recent population-based studies and meta-analyses
have shown that the risk is lower than previously described or
even similar to that of the general population.4,11–22 (Table 1).
This could be explained by methodological aspects (hospital-
based vs. population-based studies), by a true decrease in risk
due to better disease control, higher colectomy rates, use of
drugs with chemoprotective effects or more widespread
endoscopic surveillance in high-risk patients.2
Castaño-Milla et al.21 reported an overall incidence rate of
1.67/1000 PYD and incidence rates per decade were estimat-
ed at 1.01/1000, 3.75/1000 and 5.85/1000 PYD for the first,
second and third decades, respectively. In a meta-analysis of
prospective population-based studies, Jess et al.,22 found that
an average of 1.6% of patients with UC were diagnosed with
CRC during the first 14 year follow-up, and the estimated
standardised incidence ratio (SIR) was 2.39 (2.1–2.7).
Recent time-trend studies also demonstrate a decreasing
risk of CRC in UC patients. Jess et al.19 found that the relative
risk (RR) decreased from 1.34 between 1979 and 1988 to 0.57
between 1999 and 2008. In a meta-analysis by Castaño-Milla
et al.,21 the incidence rate was found to decrease from 4.29/
1000 PYD in studies published in the 1950s to 1.09/1000 PYD in











RR: Relative risk. SIR: Standardised incidence ratio.
⁎ Danish EC-IBD Cohort.
⁎⁎ Estimated from Kaplan–Meier curve.2.3. Epidemiology of colorectal cancer in
Crohn's disease
The role of Crohn's disease (CD) as a risk factor of CRC is
controversial and, compared with UC, the risk is modest. In a
meta-analysis of population-based studies in CD, Jess et al.23
estimated a pooled SIR for CRC of 1.9 (1.4–2.5). Canavan et
al.24 found a RR of 2.5 (1.3–4.7) among all CD patients, with
a higher risk for CD-colitis (RR 4.5 (1.3–14.9)); this study
estimated a cumulative risk of 2.9% at 10 years, 5.6% at
20 years and 8.3% at 30 years. A similar risk (RR 2.44 (1.56–
3.82)) was reported in a meta-analysis by von Roon et al.25
Laukoetter et al.26 reported an incidence of 0.5/1000 PYD, a
2- to 3-fold increase over the incidence of CRC in an
age-matched background population.
Friedman et al. found dysplasia (low or high grade) or CRC
in 18.5% of patients, and after a negative screening colonos-
copy the probability of developing HGD or CRC was 7% by the
10th surveillance examination.27 Basseri et al. detected LGD,
HGD or CRC in 5.6% of patients,28 but in this cohort the number
of patients with extensive colitis was lower than in Friedman's
(55% vs. 90%).2.4. Colorectal cancer in indeterminate colitis
Only one study evaluating the epidemiology of CRC in
indeterminate colitis (IC) was identified.29 Stewenius et al.,
in 1995, followed an inception cohort of 471 UC patients and
100 IC patients for a mean of 14.8 years. Three of 100 patients
with IC developed CRC, an incidence of 2.4/1000 PYD (SIR 8.6,
95% CI 1.8–25.1), compared with an incidence of 1.4/
1000 PYD in patients with UC.3. Risk factors for CRC in patients with IBD
Reported risk factors for CRC include extensive disease,4,30
young age at diagnosis,4,31 family history of CRC,32 co-existing
primary sclerosing cholangitis (PSC)33 and persistent inflam-
mation of the colon.34–36ulative incidence Risk (95% CI)
1.79 (0.85–3.28)
Colon, RR 2.75 (1.91–3.97)
Rectum, RR 1.90 (1.05–3.43)
at 30 years SIR 1.05 (0.56–1.79)
25 years SIR 1.1 (0.4–2.4)
at 30 years SIR 1.74 (1.01–3.0)
SIR 3.1 (0.1–17) ⁎
at 30 years ⁎⁎ SIR 2.7 (2.3–3.2)
RR 1.07 (0.95–1.21)
8 S. Sebastian et al.3.1. Duration and extent
Ameta-analysis by Eaden4 shows that in UC patients the risk of
CRC becomes appreciable after 10 years, and it is assumed
that risk increases with disease duration. Guidelines recom-
mend that CRC screening be started 6–10 years after onset of
symptoms in extensive colitis.37–39 However, CRC may
develop earlier, with some patients diagnosed simultaneously
with CRC and IBD, and about 9–15% presenting with CRC with
a disease duration of b6 years.40 However, data from the St
Mark's Hospital London surveillance cohort report that
the incidence of CRC remained constant or decreased with
increasing disease duration.41 In a Swedish cohort of 7607
IBD patients followed from 1960 to 2004, the incidence
of CRC (adjusted for the type and extent of IBD, sex, age
and time since diagnosis) did not show any statistically
significant trend over successive calendar periods of
follow-up.17
The risk of CRC has been found to be higher in extensive
UC than in left-sided UC, while in proctitis it is similar to
that of the general population,30 and this has been confirmed
in a recent meta-analysis.22 However, Soderlund et al.,17
analysing an original Scandinavian cohort,30 found that the RR
of cancer in patients with proctitis was 1.7 (95% CI, 1.2–2.4)
compared with that of the general population. Some authors
suggested a possible proximal extension of the disease in
patients with an initial rectal involvement.42 In Crohn's colitis,
the risk of CRC is similar to that of UC if the extension and
duration are comparable.43–463.2. Age of onset
In the original meta-analysis by Eaden et al., young age at
onset of IBD showed a trend towards a slightly increased
risk of CRC, and the incidence rate of CRC in UC diagnosed
in childhood was higher than the incidence in adults4; this
has been confirmed in a more recent meta-analysis.22 In
CD, young age has also been associated with an increased
risk of CRC.31 However, this has not been confirmed in
other studies, with some even suggesting that CRC may
develop earlier in patients diagnosed with IBD at older
ages.47–493.3. Primary sclerosing cholangitis
PSC is a recognized risk factor for CRC in patients with
colitis, with a 4-fold increase in risk compared with UC
patients without PSC.15,19,33 Dysplasia or CRC have also
been found to appear soon after the diagnosis of both
diseases in some patients (21.5 per 100 patients-years of
follow-up during the first two years).50 Moreover, current
evidence emphasizes that the risk of CRC remains after liver
transplantation.51,52
PSC can also be associated with Crohn's colitis or IC, and it
may also carry an increased risk of CRC, especially if colitis is
extensive.53 Two retrospective case–control studies have
reported conflicting results, with a Swedish study reporting
an increased risk of CRC in CD–PSC (odds ratio [OR] 6.78, 95%
CI 1.65–27.9),54 and a British study reporting no increase in
risk (OR 1.64, 95% CI 0.14–18.7).553.4. Other risk factors
Söderlund et al.,56 in the previously described cohort, found
that males had a 60% higher risk of CRC (RR 1.6, 1.2–2.2), and
a greater cumulative incidence after 40 years of disease (8.3%
vs. 3.5%); the effect of gender was limited to patients with
more than 10 years' of follow-up and in those aged
b45 years at diagnosis. No differences have been found in
CRC incidence between Caucasian and African-American IBD
patients.57
4. The pathophysiology of
colitis-associated cancer
4.1. Regulatory signals in colitis-associated
cancer (CAC)
Numerous positive and negative regulators have been
implicated in the development of CRC (see Table 2).
4.1.1. Toll-like receptors (TLRs)
A deficiency in the TLR adaptor, MyD88, has been found to
significantly reduce tumour number and size in the Apcmin/+
mouse model of intestinal tumorigenesis58,59 and the absence
of bacteria in mouse models of inflammation-associated
cancer has been shown to prevent dysplasia or cancer.60
4.1.2. Cytokines
4.1.2.1. Tumour necrosis factor-α. The absence of tumour
necrosis factor-α (TNFα) signalling in mice has been found to
be associated with decreases in mucosal damage, inflamma-
tory cell infiltrates, and cytokine expression, in response to
azoxymethane (AOM) challenge and dextran sodium sulphate
(DSS), as well as a significant reduction in tumour formation.61
4.1.2.2. Interleukin-6. High levels of interleukin-6 (IL-6) and
a soluble IL-6 receptor in IBD patients promote the accumula-
tion of T cells in the lamina propria of the colon by upregulating
anti-apoptotic factors.62,63 Moreover, increased IL-6 levels
have been observed in the serum of cancer patients and in
tumour biopsies.64 Finally, expression of IL-6 and STAT3 has
been shown to be greater in active UC and after progression to
colitis-associated cancer (CAC) than in controls or inactive
disease.65
4.1.2.3. Interleukin-21. Interleukin-21 (IL-21) was recently
found to be elevated in the gut of patients with CAC, and in
micewith CAC induced by AOM and DSS.66 IL-21-deficientmice
also developed fewer and smaller tumours than wild-type
mice.67
4.1.3. Chemokines
The atypical chemokine receptor D6 selectively recognizes
and efficiently depletes most inflammatory CC chemokines
from the extracellular milieu.68 Furthermore, expression of
D6 is increased in the lymphatic vascular bed of colonic
sections with IBD-associated colon cancer.69
TNFα induces the expression of chemokines from a
variety of colonic cells.70 Indeed, the mucosa of IBD patients
Table 2 Regulatory signals in colitis-associated cancer.
Effect Example Reference
Positive regulators
Toll like receptors Promote carcinogenesis MyD88 deficiency reduces tumour
number and size in the APCmin
mice
58–60
Procarcinogenic cytokines Promote carcinogenesis Tumour necrosis factor IL6 61–65
Chemokines Promote carcinogenesis Atypical chemokine receptor D6 68,69




IL-10 Prevent IBD related colonic neoplasia, through









Toll-IL-1R8 Inhibits IL-1 and TLR complexes signals, lack of
NF-κB activation
76–78











Variable frequency, found in inflamed,
non-neoplastic mucosa
MLH1-promoter methylation,
TGFBR2 and ACVR2 mutation—




Questionable role in IBD related neoplasia p16 INK4 and p14 ARF
methylation.
95,100–102
Serrated neoplasia pathway Present in some IBD-related neoplasia including
inflammatory mucosa—contribution unclear
V600E BRAF mutation, serrated
lesions in histology
103
Field effect Multifocal risk for neoplastic transformation as a






9Colorectal cancer in inflammatory bowel diseasehas been shown to have enhanced mRNA and protein
expression of MCP-1/CCL2,71 a CC chemokine with potent
chemotactic and activating activities for monocytes/macro-
phages. CCL2 mRNA expression has been shown to be
enhanced in the colon of the AOM-challenged mouse
model, and blocking the TNFα/TNFR axis reduced colorectal
carcinogenesis, intracolonic macrophage infiltration, and
CCL2 mRNA expression.724.1.4. Negative regulators
4.1.4.1. Interleukin-10. The demonstration that interleukin-
10 (IL-10) suppresses IL-6 and controls CAC development in a
model of microbial CRC indicates that the control of CAC
development by IL-10 may be at least partially mediated
through IL-6. Moreover, it was recently demonstrated that
patients with IL-10 receptor mutations that abrogate IL-10
signalling develop early and aggressive disease.73
4.1.4.2. Transforming growth factor-β. Transforming growth
factor-β (TGFβ) receptor-deficient transgenic mice were
found to develop significantly more tumours than wild-type
mice, while the opposite occurred in TGFβ transgenic mice.74
Additionally, mechanistic studies showed that TGFβ inhibited
IL-6-dependent tumour formation, reinforcing the conceptthat immunoregulatory molecules such as IL-10 and TGFβ
have a protective effect on intestinal inflammation and in CAC
formation.74 Supporting these data, mice transgenic for the
TGFβ inhibitor smad7 with over-expression specifically on T
cells, developed more severe colitis in response to AOM/DSS
challenge, but only a few small tumors.75
4.1.4.3. Toll-IL-1R8. A recently identified orphan member
of the IL-1 receptor family, Toll-IL-1R8 (TIR8), inhibits
signalling from IL-1R/TLR complexes,76,77 and gene transfer
experiments have revealed that it reduces the activation of
NF-κB by the IL-1R complex77 and by members of the TLR
family.76 Moreover, TIR8-deficient mice administered DSS
show dramatic weight loss, intestinal bleeding and increased
mortality, while susceptibility to CAC in the AOM challenge
model was increased.78
4.1.4.4. Nuclear factor-κB. Activation of nuclear factor-κB
(NF-κB) plays a key role in inflammation and cell proliferation
and survival.79 Regulation of NF-κB involves sequestration of
NF-κB in the cytoplasm by the inhibitor IκB, which is regulated
through phosphorylation by the IκB kinase (IKKβ) complex,
targeting it for ubiquitin-dependent degradation.80
Greten et al.81 demonstrated that IKKβ links inflammation
and tumorigenesis in a mouse model of CAC in which IKKβ was
10 S. Sebastian et al.deleted either in intestinal epithelial cells or in myeloid cells.
NF-κB has also been shown to induce vascular endothelial
growth factor and COX-2, which promote angiogenesis.80 In
addition, a subgroup of NLR proteins, including NLRP12,
inhibits transcription factor NF-κB, and it was recently
reported that NLRP12 (−/−) mice were highly susceptible to
colitis and CAC, suggesting that NLRP12 is a checkpoint of
noncanonical NF-κB, inflammation and tumorigenesis.82,83
4.1.4.5. Intestinal microbiota. Recent studies point to
alterations in the luminal microbiota in patients with IBD.
Adherent-invasive Escherichia coli is associated both with IBD
and CRC.84,85 Amore recent approach demonstratedmicrobial
changes in tumour-developing IL-10−/− mice with the preva-
lence of E. coli.86 Deletion of the bacterial polyketide
synthase (pks) genotoxic island from E. coli NC101 reduces
the development of dysplasia and cancer, independent of
inflammation.
4.2. Molecular pathways of CAC
CRC has been considered to develop through well defined
pathways, including chromosomal instability (CIN), microsat-
ellite instability (MSI) and, most recently, the CIMP pathway.87
There have been previous attempts to distinguish IBD related to
sporadic colonic neoplasia88 with some success. A few studies
looked at different markers and genes related to CIN, such as
aneuploidy, loss of heterozygosity (LOH) and genomic gains or
losses of various genes89–91 but observations are not consistent.
Notably, p53 mutations occur earlier in IBD-related
neoplasia, probably a key initiating event,92 than APC
mutations, which occur later than commonly observed in
sporadic colorectal neoplasia.93,94 Allelic deletions of p53
were observed in approximately 50% to 85% of colitis-
associated tumours.95 p53 LOH has been shown to correlate
withmalignant potential in the colon. Mutations in some other
commonly mutated CIN pathway genes of sporadic CRC such as
DPC4 and KRAS were uncommon in CAC.96 The CIN pathway
can contribute to up to 85% of CAC, while the role of the MSI
pathway is less clear. However, MSI has been found in up to
45% of cases.97–99 MSI has been demonstrated in histologically
normal colonic mucosa of patients with UC, perhaps as a risk
indicator for neoplastic progression.100 A paper looking at MSI
and methylation status of 124 IBD-related colonic neoplasias
from 78 patients,101 showed 19/124 (9.6%) neoplastic lesions
to be MSI-high (MSI-H). Methylation profile, tested by HPP1
and RAB32 methylation, was found to be independent of
MSI status, with such methylation found in 28/61 (46%) and
20/60 (33.3%) carcinomas, while HPP1 methylation was
frequently (~50%) observed in dysplastic mucosa and even in
nondysplastic mucosa (7%). In another study,102 mutational
events secondary to MSI were found to be similar in IBD- and
non IBD-related colonic neoplasia. MSI-H IBD neoplasias were
not more frequently right sided and there was no age or sex
association, whereas sporadic MSI-H CRC was more prevalent
in older women. IBD MSI-H tumours were more advanced and
less often poorly differentiated than sporadic MSI-H tumours.
Data regarding themethylation pathway are contradictory.
Some evidence suggests that the involvement of this pathway
is more prevalent in IBD-related neoplasia.101 Methylation of
CPG islands in several genes can precede dysplasia and can bedetected throughout the colon in UC patients.103 p16INK4 has
frequently been shown to be hypermethylated in patients
with UC even in non-dysplastic mucosa, and is considered a
marker for the CIMP pathway.98 An additional methylated
gene is p14 RF, an indirect regulator of p53.104 Recent
evidence does not support the co-occurrence of methylation
with IBD CRC neoplasia.105
The serrated neoplasia pathway, characterized by V600E
BRAF mutations, has been recently shown to explain some of
the IBD-related neoplastic colonic lesions.106 Clonality of
colitis-associated neoplasia has been shown in several crypts
from the same colitis-associated neoplastic lesions.92,107 As
in sporadic CRC, genomic transformation probably takes
place in stem cells at the base of the crypt, as mutations
have been shown to spread. These cells apparently sense
signals from the microenvironment and the epithelial
mesenchymal interaction.108
4.3. The field effect
One of the main differences between sporadic and IBD-related
colonic neoplasia is that in IBD the entire colonic mucosa
carries risk for neoplastic transformation that can be
multifocal, as opposed to one or few premalignant adenomas
or cancers in sporadic cases.109
Aneuploidy is a marker for genomic instability and has been
shown in morphologically normal mucosal cells in IBD. Studies
in UC patients with consecutive colonoscopies indicate that cell
populations with aneuploidy expand in location over time.110
Aneuploidy does not correlate morphologically with dysplasia
and is probably more widespread. Many genomic alterations,
including methylation, have been shown in morphologically
normal colonicmucosa in IBD patients.92,107 p53mutations that
are an initial event in IBD-associated neoplasia can be found in
nondysplastic mucosa.95 Two recent studies92,107 looked into
individual crypts and found the samemutations, mainly in TP53
KRAS and CDKN2A, present both in neoplasia and in
nondysplastic mucosa, even long before tumour development,
strongly supporting the concept of a precancerous field effect.
The cause of the field effect can be explained by the
constant re-epithelialization of ulcerated and chronically
inflamed colonic mucosa by abnormal healing clones that
expand,97 as well as local environmental changes such as
dysbiosis of themicroflora, which can cause the appearance of
these mutations in several spots.111
5. Outcome of colorectal cancer in IBD
During the last 40 years there have been a few small reports
looking at the outcome of CRC in UC9,112–115 and CD.116,117
The overall 5-year survival rates in these reports range
from 33.5% to 55.1% for UC and 18% to 46% for CD, with no
significant differences compared with non-IBD cases of CRC.
Over the last 16 years, a number of larger multi-centre
cohort studies and population-based reports have been
published. Bansal and Sonnenberg118 showed a trend
(p = 0.0681) towards decreased risk of cancer-related death in
CRC among patients with IBD (n = 371) compared with sporadic
CRC (n = 52 243), but no difference between CD (n = 134) and
UC (n = 237). A 20-year follow-up study from the Mayo Clinic
compared IBD-related (UC = 241 and CD = 49) CRC with age-
11Colorectal cancer in inflammatory bowel diseaseand sex-matched sporadic CRC.119 IBD-related cancers were
more proximal, with only 55% distal to the splenic flexure,
compared with 78% among sporadic CRC. Cases of IBD-related
CRC were more often grade 3 or 4 tumours (40%) compared
with sporadic tumours (33%), and were also more often
mucinous (UC 20%, CD 24% and sporadic 13%). Despite this, no
differences were found in overall survival between sporadic
and IBD-related CRC. Two Danish population-based studies
looked specifically at UC-120 and CD-121 related CRC compared
with sporadic CRC. In the study on UC by Jensen et al.120 71 259
sporadic CRC cases during 1977–1999 were compared with 279
UC-related cancers. Cancer stage, and rates of lymph node and
distant metastasis were similar between the two groups. The
overall mortality rates at 1 and 5 years after cancer diagnosis
were increased in UC-related CRC compared with sporadic
cancers (1.24 (95% CI 1.02–1.51) and 1.17 (95% CI 1.01–1.36),
respectively). In a similar study by Larsen et al.,121 71 438
sporadic CRC cases were compared with 100 CD-related CRC
cases. The hazard ratios for death at 1 and 5 years after cancer
diagnosis were 1.82 (95% CI 1.36–2.43) and 1.57 (95% CI 1.24–
1.99), respectively. Both in UC and CD, CRC diagnosed
b60 years of age was shown to have a worse outcome,
especially within the first year with a hazard ratio of 1.92
(95% CI 1.29–2.87). Brackmann et al.122 published a
population-based study from 1962 to 2005 on 81 780 sporadic
cases of CRC and 60 patients with IBD-related dysplasia or CRC
(CD colitis n = 6, UC n = 54). No differences were found
regarding cancer stage or distant metastasis at the time of
CRC diagnosis. The mortality rate ratio (MRR) was 3.71 (95%
CI 2.54–5.42) for IBD-related CRC, compared with sporadic
cancers mainly attributable to multifocal dysplasia or
cancers, for which the MRR was 4.27 (95% CI 2.83–6).
Survival after localised IBD-related CRC was similar to that
of sporadic CRC.
In another study, the outcome in UC patients (n = 20) was
compared with that in CD patients (n = 14) diagnosed with
CRC between 1990 and 2007.123 CRC in CD was found to be
associatedwith worse outcome in terms of 5-year disease-free
survival, 43% and 31% vs. 70% and 63% in UC (p = 0.01
respectively). In a Swedish population-based study,124 spo-
radic CRC cases (n = 112 948) were compared with tumours
occurring in IBD patients (n = 251), all with similar tumour
stage at CRC diagnosis. Apart from rectal cancer in CD, the
CRC-related mortality was increased among IBD patients, with
hazard ratios for colon cancer of 2.08 (95% CI 1.46–2.96) in CD,
1.32 (95% CI 1.02–1.72) in UC and 1.77 (95% CI 1.22–2.56) for
rectal cancer in UC. Furthermore, this study revealed that IBD
patients b60 years at time of diagnosis and males had a worse
outcome.
Some studies have found no difference between IBD and
sporadic CRC in terms of survival. Peyrin-Biroulet et al.
analysed data from the Burgundy digestive cancer registry in
France during 1976–2008 (sporadic n = 19 413 and IBD
related n = 38).125 As shown previously, IBD patients were
younger at the time of CRC diagnosis, 56.9 years vs.
70.9 years (p b 0.001). A trend towards an excess death
rate was found among IBD patients with CRC (hazard ratio
1.46 95% CI 0.94–2.27). Another more recent US study126
compared 29 CRC patients with CD and 53 with UC with
13 938 sporadic CRC patients. Mortality from CRC was 2.3
(95% CI 1.6–3.0) times higher in CD and 2.0 (95% CI 1.3–2.7)
times higher in UC.In summary, the available literature shows an impaired
outcome of CRC in IBD, with a 2-fold increase in mortality
compared with sporadic cancers, but without major differ-
ences between UC and CD except for a more advanced
tumour stage at the time of diagnosis in CD patients. It is
worth noting that for IBD, the presence of CRC is often not
known prior to surgery. Male sex and young age are factors
associated with poor outcome.
6. Chemoprevention of colorectal cancer in IBD
A number of agents are potential chemopreventives in IBD,
such as 5-aminosalicylates (5-ASAs), ursodeoxycholic acid
(UDCA), folic acid and azathioprine.
6.1. 5-Aminosalicylates
5-ASA compounds, used extensively in the management of
IBD, particularly UC, have been identified as candidate
chemopreventive agents.127 The mechanism of action of
mesalazine in chemoprevention is diverse, interfering with
many pathways in CRC cell biology, rather than simply
controlling inflammation. Actions include activation of the
PPAR gamma pathway, inhibition of lipoxygenase and
cyclooxygenase mediators, free radical scavenger and
antioxidant functions, and ability to inhibit interleukins.128
Early evidence comes from a community-based study
cohort of 175 patients with UC by Moody et al.129 who
demonstrated a 10-fold reduction in the incidence of CRC in
patients on long-term sulphasalazine. In a case-controlled
study, Pinchowski et al.130 studied this aspect in IBD patients
grouped by the duration of 5-ASA use. Patients who had used
sulphasalazine for ≥3 months had a 62% risk reduction
compared with patients with a shorter duration of use. In a
further case-controlled study, Eaden et al.131 compared 102
patients with UC-related CRC withmatched controls, finding a
75% risk reduction for CRC among patients with regular 5-ASA
use (OR 0.25; 95% CI 0.13–0.48; p b 0.00001). The benefit
persisted after adjusting for variables such as disease extent
and disease duration (OR 0.19, 95% CI 0.06–0.61; p = 0.006). A
more recent large population-based general practise database
study from the UK132 found that regular users of 5-ASAs
(defined as N6 prescriptions in the preceding 12 months) had a
40% reduced risk of CRC (adjusted OR 0.60 (0.38–0.96)).
However, not all studies support a protective effect. In a
large UC surveillance cohort at St Mark's Hospital, London,
primarily designed to examine risk factors for colorectal
neoplasia, use of mesalazine for ≥10 years was associated
with a more modest and non-significant decrease in CRC risk
(OR 0.65; 95% CI 0.26–1.62).133 In addition, this study
reported an unexpected increase in risk of CRC in patients
taking long-term sulphasalazine. Similarly, Ullman et al.134
found no evidence of an effect of mesalazine exposure on
subsequent development of advanced neoplasia. Terdiman135
compared CRC patients registered on a large administrative
claims database in California with controls, finding that 5-ASA
therapy of any dose for a duration of 1 year before diagnosis of
CRC was not associated with a reduction in CRC risk (OR 0.97,
95% CI 0.77–1.22). Bernstein et al. found a trend towards
increased cancer risk associated with the use of 5-ASAs within
2 years of a cancer diagnosis, indicating perhaps that the
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UC.136
The most compelling data supporting a beneficial effect
of 5-ASAs come from a meta-analysis of 9 observational
studies involving a total of 1932 patients, finding a 49%
reduction in the risk of CRC or CRC/dysplasia with regular
use of 5-ASAs.137 The pooled analysis showed a protective
association between use of 5-ASA and CRC (OR 0.51, 95% CI
0.37–0.69) and for the combined end point of CRC/dysplasia
(OR 0.51, 95% CI 0.38–0.69). A recent systematic review138
including 4 observational studies focused on non-referral
studies indicated a chemopreventive benefit with 5-ASAs
with an adjusted OR of 0.95 (95% CI 0.66–1.38), but there
was moderate heterogeneity (I2 = 58.2%; p = 0.07).
Four studies looked at the dose needed to provide a
chemoprevention benefit. A study by van Staa et al.132 found
a doubled risk reduction among those on daily doses above
1.2 g/day compared with those taking b1.2 g/day, but a
protective effect was observed in both groups (adjusted OR
0.28 and 0.56, respectively). Similar results were shown by
Eaden et al.131 where mesalazine at doses of 1.2 g or more
reduced CRC risk by 91% compared with no treatment (OR
0.09, 95% CI 0.03–0.28) but a protective effect was still found
with lower doses (OR 0.08; 95% CI 0.08–0.85). In amore recent
case-controlled study involving 1594 IBD patients that includ-
ed 18 CRC patients, cumulative aminosalicylate dose of over
4500 g reduced the risk of CRC by 97% after adjusting for
disease extent and duration.139
Overall, despite the lack of good quality prospective
randomised trials, there is sufficient evidence now to
recommend the use of 5-ASAs for the chemoprevention of
CAC. However, a number of unanswered questions remain.
There is little data from which to establish recommendations
for when to initiate therapy, the duration of therapy needed
to achieve the benefit of chemoprevention and whether the
effect lasts after cessation of therapy. Future studies should
also identify those groups at highest risk among whom the
benefit may be higher, and whether 5-ASA can inhibit
progression of dysplasia to cancer. The anti-mutational effect
of 5-ASA may also be useful in individuals with Lynch
syndrome.140,1416.2. Ursodeoxycholic acid
The first indication of a potential chemoprotective effect of
UDCA in UC came from a retrospective study of 59 patients
with PSC and UC, of whom 41 were treated with UDCA142 in
which a lower prevalence of dysplasia was reported in the
UDCA-treated group (OR 0.18; p = 0.005) with a 40% difference
in risk between the two groups. The protective effect appeared
to persist after adjusting for age, duration of colitis and
concomitant sulfasalazine use (adjusted OR 0.14, 95% CI 0.03–
0.64). In a placebo-controlled trial in PSC patients with UC
(median disease duration 13 years, follow-up time 6.5 years),
designed to detect improvement in liver function, UDCA was
associated with a 74% risk reduction for CRC and dysplasia (RR
0.26, 95% CI 0.07–0.99).143 Due to the limited number of
colonic biopsies performed in the study compared to the
current surveillance guidelines, the result may be biassed.
Further evidence of the benefit of UDCA came from a proof
of concept study in IBD patients with pre-existing low-gradedysplasia and DNA aneuploidy randomised to receive UDCA or
placebo.144 The primary outcome, defined as the need for
colectomy for the progression of dysplasia, was reached in 2
patients in the placebo group and none in the UDCA-treated
group. This study was limited by very small patient numbers,
short treatment duration and the low doses of UDCA used, but
it does indicate that UDCA may halt the progression of
dysplasia in high-risk patients with extensive colitis and
pre-existing premalignant lesions.
The early positive findings for UDCA as a chemopreventive
agent have not been replicated in more recent studies,
including studies with more patients. In a cohort study that
included 120 patients,Wolf et al.145 found no difference in the
risk of developing dysplasia or carcinoma, although they did
show a reduction in mortality in the UDCA group. More recent
studies suggest that the duration of treatment and the dose
of UDCA are important factors in chemoprevention.146–150
Eaton and et al.148 examined the effects of high-dose
(28–30 mg/kg/day) UDCA on the development of colorectal
neoplasia in 56 patients with UC and PSC with a follow-up
duration of 235 patient years. Patients who received high-
dose UDCA had a significantly higher risk of developing
colorectal neoplasia during the study than those who received
placebo (HR: 4.44, 95% CI 1.30–20.10; p = 0.02). In another
study, also using high-dose UDCA (17–23 mg/kg), there was a
similar frequency of dysplasia or cancer after 5 years in
patients originally assigned to UDCA or placebo (13% vs. 16%),
and no difference was detected in dysplasia/cancer-free
survival after 5 years of therapy (13% and 16%) or 10 years of
follow-up (30% and 27%).149 In a study in post-transplant
patients with PSC, use of 5-ASA or UDCA was shown on
multivariate analysis to be associated with an increased risk of
CRC.150 A large randomised study estimating the survival
advantage in PSC patients of high-dose 5-ASA failed to
demonstrate any reduction in CRC risk.151 In contrast, a
prospective study from Germany in 120 patients with IBD and
PSC found that the annual incidence of CRC increased up to
6 years after the start of UDCA but subsequently de-
creased.152 A recent meta-analysis of 4 studies, including
281 patients, reported that UDCA was not associated with any
improvement in the risk of CRC (OR 0.53; 95% CI: 0.19–1.48;
p = 0.23) compared with no UDCA or placebo.153
Overall, studies so far suggest that the role of UDCA as a
chemopreventive agent remains controversial, particularly
at high doses. Larger randomised prospective studies
including those comparing high doses versus low doses are
needed to reach a conclusion. However, this is unlikely given
the rarity of treatment-naïve PSC patients with colitis, and
the long follow-up necessary.6.3. Immunomodulators
There is increasing evidence that chronic inflammation
favours the development of cancer in IBD, and hence mucosal
healing with immunomodulators or biologics may prevent CRC
in IBD.154 However, there is insufficient data on the role of
immunomodulators in chemoprevention. In a single-centre
study of UC patients treated with azathioprine and followed
for 17 years, no patient developed cancer.155 In a further
cohort study from New York of 315 patients followed for an
average of 8 years, azathioprine (AZA)/6-mercaptopurine
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CRC.156 Three further studies examined chemoprevention by
6MP and AZA as chemoprophylaxis, although not as the
primary endpoint.133,142,157 Rutter et al.133 showed a
non-significant trend towards a protective effect of azathio-
prine use for 1–5 years, or greater than 5 years, with ORs of
0.34 (95% CI 0.09–1.25) and 0.73 (95% CI 0.30–1.78),
respectively. Lashner et al.157 reported that the use of
azathioprine for ≥6 months had no protective effect (RR
1.12, 95% CI 0.26–4.17). A similar result was reported by Tung
et al.142 These studies were retrospective cohort studies with
no data available on the dose used or duration of treatment.
In a nested case–control study using a UK primary care
database,132 among 5-ASA users who had also used oral
glucocorticoids or immunosuppressants in the previous
6 months there were no differences in the risk of CRC between
regular and irregular 5-ASA use (adjusted OR 1.21 (95%
CI 0.43–3.45)). In contrast, regular 5-ASA use was associated
with a reduced risk of CRC in non-users of oral glucocorticoids or
immunosuppressants (adjusted OR 0.53 (95% CI 0.30–0.92).129 In
amore recent nested case–control study in North America, using
immunosuppressive therapy (OR 0.3; 95% CI 0.16–0.56;
p b 0.001) or anti-TNFα (OR 0.09; 95% CI 0.01–0.68; p b 0.02)
was protective in terms of risk of IBD-related CRC.20 Interesting-
ly, the overall risk of CRC in this cohort was much lower than
previously reported, with an overall risk of 0.04%.20
The association between thiopurine and or 5-ASA use and
the risk of advanced neoplasia (AN), including high-grade
dysplasia and colorectal cancer, was recently investigated in
a large cohort of patients with IBD in the Netherlands.158
Thiopurine use was associated with a significantly decreased
risk of AN (adjusted HR 0.10, 95% CI 0.01 to 0.75). 5-ASA
therapy also had a protective effect against AN, but this was
not statistically significant (adjusted HR 0.56, 95% CI 0.22 to
1.40).
Recent experimental data identifying TNFα as a mediator
involved in initiation and progression of CAC has not yet been
reflected in clinical trials, and other risks will preclude their
use for the sole aim of chemoprevention. The results from
the GETAID CESAME cohort have not yet been fully reported,
but preliminary data do not support a chemopreventive role
of AZA.1596.4. Folic acid
Lashner et al.157 reviewed data from 99 patients with
pancolitis enrolled in a 7-year surveillance programme and
studied the effect of folate supplementation on the rate of
neoplasia development using case–control methodology.
Folate supplementation was associated with a 62% lower
incidence of neoplasia but this was not statistically signifi-
cant (OR, 0.38; 95% CI, 0.12–1.20). The same group also
reported a similar non-significant trend towards a protective
effect and dose–response effect of folate supplementation
of ≥6 months in a subsequent cohort study.160 In this study,
the adjusted RR of neoplasia for patients taking folate was
0.72 (95% CI 0.28–1.83). The risk of neoplasia varied with
folate dose (RR, 0.54 for 1.0 mg folate; RR, 0.76 for 0.4 mg
folate in a multi-vitamin, compared with no folate). The
degree of dysplasia also varied with folate use (RR for
cancer, 0.45; RR for high-grade dysplasia, 0.52; RR forlow-grade dysplasia, 0.75, compared with patients without
dysplasia) (p = 0.08). An experimental study on cell kinetics
using immunohistochemistry following 3 months of folic acid
or placebo supplementation in 12 colitis patients revealed a
reduction in cell proliferation.161 However, the role of folic
acid has not yet been tested in large randomised controlled
trials.
Overall, while there is no clear data to support routine
the use of folic acid, there appears to be a trend towards
benefit. Since folic acid is inexpensive and safe it may be
considered in selected patients at the clinician's discretion.
6.5. Statins
Experimental data from mice indicate that statins may have
a protective effect against colitis-associated carcinogenesis,
primarily by the induction of selective apoptosis of colon
cancer cells.162 In a population-based case–control study,163
statin therapy was associated with a modest reduction
in CRC in the non-IBD population, but a substantial 94% risk
reduction in patients with IBD was observed in a subset
analysis of 55 IBD patients. Furthermore, a recent meta-
analysis of 18 trials on statin use in hypercholesterolemia
showed only limited benefit in the setting of general
population.164 Overall, further studies are needed in high-
risk IBD patients to test the results of initial experimental
studies.
6.6. Chemoprevention in CD
The role of chemoprevention in CD has not been well
studied, and available data comes from studies with small
numbers of CD patients and do not give any firm conclusions.
However, a non-significant trend for a protective effect has
been reported with regular 5-ASA use (OR 0.30; 95% CI 0.05–
1.17; p = 0.10) in at least one study.165
7. Conclusions and areas for future research
Recent data show that CRC risk is decreasing but it still
remains a major clinical problem in IBD patients. Better
control of intestinal inflammation is likely to be the major
reason. Future areas of investigation should focus on
understanding better the key pathogenic pathways. In
addition, the impact of all the novel medications including
anti-TNF in decreasing CRC risk needs to be better assessed,
even though interventional studies appear to be unethical
and not feasible when is matter of choosing between
treating or not inflammation. Large prospective cohorts
can help us to further investigate and identify the risk
factors to develop CRC and to assess the efficacy of IBD
related drugs in reducing the risk. Finally, from a surgical
point of view the collection of data from cohort studies and
managing CRC in similar pathways of care can provide better
data on survival and disease related outcomes.
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